ReviewDiabetes therapy : research, treatment and education of diabetes and related disorders2020
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials.
Review in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data.Journal of nephrology · 2024Pooled it
- Weight loss by sodium-glucose co-transporter 2 inhibitor canagliflozin is followed by rebound in db/db mice but maintained in fat-fed mice via circadian rises in body temperature and locomotor activity.The journal of physiological sciences : JPS · 2026Article
- Effects of SGLT2 inhibitors on NSAID-associated acute kidney injury in type 2 diabetes: a claims-based cohort study.BMC nephrology · 2026Article
- Care pathways for patients with cognitive impairment and chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions.International journal of molecular sciences · 2024Review
- SGLT2 inhibitors: cardiac superheroes with caveats.The British journal of cardiology · 2024Article
- Characterizing Prescribing Patterns of Diabetes Medications at an Adult Medicine Clinic: A Focus on Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.Diabetes spectrum : a publication of the American Diabetes Association · 2024Article
- Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.Heart failure reviews · 2023Review
- Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond.Endocrinology and metabolism (Seoul, Korea) · 2023Article
- Diabetic kidney disease in children and adolescents: an update.Pediatric nephrology (Berlin, Germany) · 2022Review
- Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease.Journal of diabetes investigation · 2022Review
- Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs.The Korean journal of internal medicine · 2022Review
- Cellular and metabolic effects of renin-angiotensin system blockade on glycogen storage disease type I nephropathy.Human molecular genetics · 2022Article
- Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Review
- Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR.Kidney international reports · 2021Article
- Sodium Intake and Proteinuria/Albuminuria in the Population-Observational, Cross-Sectional Study.Nutrients · 2021Observational
- The Current and Potential Therapeutic Use of Metformin-The Good Old Drug.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Review
- Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection.International Journal of Cardiology. Hypertension · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of chronic kidney disease (CKD) in people with diabetes is commonplace, and is frequently associated with a significant and unfavourable impact on patient outcomes along with a substantial economic burden. With the development of novel classes of drug therapies in diabetes, there has been a recent focus on cardiovascular safety measures, with dedicated cardiovascular outcome trials (CVOTs) carried out for all new diabetes medications. More recently, there has been a growing regulatory view that such trials should report more specific renal outcomes to ensure simpler comparability between drugs and drug classes. This article explores some of the possible mechanisms by which these drugs may improve renal function in people with diabetes, and it reviews important CVOTs that have reported renal outcomes to date. These include CVOTS of sodium-glucose cotransporter-2 inhibitors (EMPA-REG OUTCOME study, CANVAS study, CREDENCE trial, DECLARE-TIMI trial and DAPA-HF study), dipeptidyl peptidase-4 inhibitors (EXAMINE trial, SAVOR-TIMI 53, TECOS trial and CARMELINA trial) and glucagon-like peptide-1 analogues (ELIXA trial, LEADER trial, SUSTAIN-6 trial, PIONEER-6 trial, EXSCEL trial, HARMONY Outcomes study and the REWIND study). Ongoing cardiovascular and renal outcome studies such as Dapa-CKD, EMPA-KIDNEY, EMPEROR-Preserved and EMPEROR-Reduced are also discussed. The heterogeneity of patient characteristics and reported renal outcomes, which hinders comparisons between trials and drug classes, is highlighted. Novel classes of diabetes therapies present an important opportunity for nephroprotection beyond the blockade of the renin-angiotensin-aldosterone system in this high-risk group. Clinicians should be aware of such benefits when prescribing these medications for people with, and possibly those without, type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.